Actively Recruiting
A Study Investigating Oral Semaglutide in People with Open-Angle Glaucoma
Led by Glostrup University Hospital, Copenhagen · Updated on 2025-01-24
126
Participants Needed
1
Research Sites
204 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The aim of this clinical trial is to investigate whether oral semaglutide can be used to treat open-angle glaucoma. The main question it aims to answer is: Does oral semaglutide safely improve inner retinal function in patients with open-angle glaucoma as measured by the photopic negative response of the electroretinogram. Researchers will compare oral semaglutide to a placebo (a look-alike substance that contains no drug). Participants will: * Take semaglutide or a placebo every day for 6 months. * Visit the clinic 5 times in total for tests and interviews: At baseline (the first day they are included in the study), after 1 month, after 2 months, after 3 months, and after 6 months (the last day they are included in the study).
CONDITIONS
Official Title
A Study Investigating Oral Semaglutide in People with Open-Angle Glaucoma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Ability to read and speak Danish
- 45 years or older at the time of inclusion
- Visual acuity equal to or above 0.5 in the study eye
- Diagnosis of primary open-angle glaucoma with mean deviation of 16 dB or less and reliable visual field loss in at least one eye
- Currently receiving intraocular pressure-lowering glaucoma treatment
- Nerve fiber layer defects identified by OCT
You will not qualify if you...
- Diabetes or renal impairment
- Significant eye disease other than glaucoma, including ocular trauma
- Eye inflammation or infection within three months before inclusion
- Intraocular surgery within three months before inclusion
- Current smoker
- Pregnant or breastfeeding
- Females of childbearing potential not using adequate contraception
- Allergy to drug ingredients used in the trial
- Untreated severe systemic diseases or malignancies
- Previous history of pancreatitis
- Body mass index below 18.5
- Current treatment with Dipeptidyl peptidase-4 inhibitors, other GLP-1 receptor agonists, insulin or insulin analogues, sulfonylurea, systemic corticosteroids, or immunosuppressants
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Department of Ophthalmology, Rigshospitalet
Glostrup Municipality, Denmark, 2600
Actively Recruiting
Research Team
M
Miriam Kolko, MD, PhD
CONTACT
A
Anna-Sophie Thein
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here